Citations

Clear

590 citation(s) found for "Ho, Ben".

Assessment of a Personalized Approach to Predicting Postprandial Glycemic Responses to Food Among Individuals Without Diabetes
Mendes‐Soares, Helena , Raveh-Sadka, Tali, Azulay, Shahar, Edens, Kim, Ben‐Shlomo, Yatir , Ofek, Tal, Bachrach, Davidi, Stevens, Josh , Segal, Lihi, Kashyap, Purna , Nelson, Heidi , Colibaseanu, Dorin , Cohen, Yossi

Mayo Clinic

JAMA Network Open | February 8, 2019 | Volume: 2 | Issue: 2 | Pages: e188102

10.1001/jamanetworkopen.2018.8102 | PMID 30735238 Get It

TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer
Connolly, Roisín M. , Leal, Jeffrey P. , Sólnes, Lilja B. , Huang, Chiung‐Yu , Carpenter, Ashley , Gaffney, Katy, Abramson, Vandana G. , Liu, Minetta C. , Rimawi, Mothaffar F. , Specht, Jennifer M. , Storniolo, Anna Maria , Valero, Vicente , Krop, Ian E. , Camp, Melissa , Cimino‐Mathews, Ashley , Wahl, Richard L. , Abramson, Vandana G , Rimawi, Mothaffar , Specht, Jennifer , Wahl, Richard L , Gaffney, Katy, Carey, Lisa A. , Vaklavas, Christos , Winer, Eric P. , Miller, Robert S. , Wolff, Antonio C. , Park, Ben Ho , Stearns, Vered , Huang, Chiung-Yu

Mayo Clinic

Journal of Clinical Oncology | February 5, 2019 | Volume: 37 | Issue: 9 | Pages: 714-722

10.1200/jco.2018.78.7986 | PMID 30721110 Get It

PURPOSE Predictive biomarkers to identify patients with human epidermal growth factor receptor 2 (HER2)–positive breast cancer who may benefit from targeted therapy alone are required. We hypothesized that early measurements of tumor maximum standardized uptake values corrected for lean body mass (SULmax) on [ 18 F]fluorodeoxyglucose positron emission tomography/computed tomography would predict pathologic complete response (pCR) to neoadjuvant pertuzumab and trastuzumab (PT). PATIENTS AND METHODS Patients with stage II/III, estrogen receptor–negative, HER2-positive breast cancer received four cycles of neoadjuvant PT. [ 18 F]Fluorodeoxyglucose positron emission tomography/computed tomography was performed at baseline and 15 days after PT initiation (C1D15). Eighty evaluable patients were required to test the null hypothesis that the area under the curve of percentage of change in SULmax by C1D15 predicting pCR is less than or equal to 0.65, with a one-sided type I error rate of 10%. RESULTS Eighty-eight women were enrolled (83 evaluable), and 85% (75 of 88) completed all four cycles of PT. pCR after PT alone was 34%. Receiver operating characteristic analysis yielded an area under the curve of 0.76 (90% CI, 0.67 to 0.85), which rejected the null hypothesis. Between patients who obtained pCR versus not, a significant difference in median percent reduction in SULmax by C1D15 was observed (63.8% v 33.5%; P < .001), an SULmax reduction greater than or equal to 40% was more prevalent (86% v 46%; P < .001; negative predictive value, 88%; positive predictive value, 49%), and a significant difference in median C1D15 SULmax (1.6 v 3.9; P < .001) and higher proportion of C1D15 SULmax less than or equal to 3 (93% v 38%; P < .001; negative predictive value, 94%; positive predictive value, 55%) were observed. CONCLUSION Early changes in SULmax predict response to four cycles of PT in estrogen receptor–negative, HER2-positive breast cancer. Once optimized, this quantitative imaging strategy may facilitate a more tailored approach to therapy in this setting.
Transcriptome-Wide Association Study Identifies New Candidate Susceptibility Genes for Glioma
Atkins, Isabelle, Kinnersley, Ben , Ostrom, Quinn T. , Labrèche, Karim , Il’yasova, Dora , Armstrong, Georgina , Eckel‐Passow, Jeanette E. , Schoemaker, Minouk J. , Nöthen, Markus M. , Barnholtz‐Sloan, Jill S. , Simon, Matthias , Rajaraman, Preetha , Shildkraut, Joellen, Bernstein, Jonine L. , Jöckel, Karl‐Heinz, Lai, Rose , Claus, Elizabeth B. , Johansen, Christoffer , Wrensch, Margaret , Melin, Beatrice , Jenkins, Robert B. , Sanson, Marc , Bondy, Melissa L. , Houlston, Richard S. , Swerdlow, Anthony J , Houlston, Richard S , Barnholtz-Sloan, Jill S , Nöthen, Markus M , Sanson, Marc , Schoemaker, Minouk J , Armstrong, Georgina , Swerdlow, Anthony J. , Chanock, Stephen Jacob , Hoffmann, Per , Olson, Sara H. , Ostrom, Quinn T

Mayo Clinic

Cancer Research | February 1, 2019 | Volume: 79 | Issue: 8 | Pages: 2065-2071

10.1158/0008-5472.can-18-2888 | PMID 30709929 Get It

Abstract Genome-wide association studies (GWAS) have so far identified 25 loci associated with glioma risk, with most showing specificity for either glioblastoma (GBM) or non-GBM tumors. The majority of these GWAS susceptibility variants reside in noncoding regions and the causal genes underlying the associations are largely unknown. Here we performed a transcriptome-wide association study to search for novel risk loci and candidate causal genes at known GWAS loci using Genotype-Tissue Expression Project (GTEx) data to predict cis-predicted gene expression in relation to GBM and non-GBM risk in conjunction with GWAS summary statistics on 12,488 glioma cases (6,183 GBM and 5,820 non-GBM) and 18,169 controls. Imposing a Bonferroni-corrected significance level of P &lt; 5.69 × 10−6, we identified 31 genes, including GALNT6 at 12q13.33, as a candidate novel risk locus for GBM (mean Z = 4.43; P = 5.68 × 10−6). GALNT6 resides at least 55 Mb away from any previously identified glioma risk variant, while all other 30 significantly associated genes were located within 1 Mb of known GWAS-identified loci and were not significant after conditioning on the known GWAS-identified variants. These data identify a novel locus (GALNT6 at 12q13.33) and 30 genes at 12 known glioma risk loci associated with glioma risk, providing further insights into glioma tumorigenesis. Significance: This study identifies new genes associated with glioma risk, increasing understanding of how these tumors develop.
Predictors of mortality in patients with non‐anterior ST‐segment elevation myocardial infarction: Analysis from the HORIZONS‐AMI trial
Huang, Xin , Redfors, Björn , Mehran, Roxana , Zhang, Yiran , McAndrew, Thomas , Ben‐Yehuda, Ori , Mintz, Gary S. , Stone, Gregg W. , Mehran, Roxana , Chen, Shmuel , Gersh, Bernard J.

Mayo Clinic

Catheterization and Cardiovascular Interventions | January 28, 2019 | Volume: 94 | Issue: 2 | Pages: 172-180

10.1002/ccd.28096 | PMID 30690854 Get It

Abstract Objectives We sought to identify clinical, electrocardiographic (ECG), and angiographic characteristics that are predictive of 3‐year mortality after primary percutaneous coronary intervention (PCI) in patients with non‐anterior ST‐elevation myocardial infarction (NA‐STEMI) from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS‐AMI) trial. Background Which patients with NA‐STEMI undergoing PCI have a poor prognosis is uncertain. Methods NA‐STEMI was defined as ST‐segment elevation in lateral (V5, V6, I, aVL), inferior (II, III, aVF), or inferolateral (I, II, III, aVF, and V5‐V6) ECG leads or posterior myocardial infarction with ST‐segment depression of ≥1 mm in ≥2 contiguous anterior leads. Cox regression was used to identify independent predictors of 3‐year mortality. Missing data were imputed using multiple imputation. Results In HORIZONS‐AMI, 2,578/3,602 patients had no prior coronary artery bypass grafting, underwent single‐vessel PCI, and had baseline ECG data assessed in an independent core laboratory. Among them, 1,495 (58.0%) had NA‐STEMI. Patients with NA‐STEMI had lower 3‐year mortality risk than those with anterior STEMI (4.5% versus 7.1%, P = 0.004). The independent predictors of increased 3‐year mortality in NA‐STEMI were older age (median > 59.0 years), diabetes, reduced LVEF (≤50%), Killip class ≥2, post‐procedure TIMI flow 0–2 versus 3, renal insufficiency, and ST‐resolution <30% at 60 min post‐PCI. Patients with 0, 1, 2, 3, and ≥4 of these risk factors had 3‐year mortality rates of 1.8%, 2.3%, 3.1%, 6.1%, and 36.3%, respectively ( P < 0.0001). Conclusions Although NA‐STEMI carries a better prognosis than anterior STEMI, high‐risk patient cohorts with NA‐STEMI may be identified who have substantial 3‐year mortality.
Shared Medical and Environmental Risk Factors in Dry Eye Syndrome, Sjogren’s Syndrome, and B-Cell Non-Hodgkin Lymphoma: A Case-Control Study
Ben‐Eli, Hadas , Aframian, Doron J. , Ben‐Chetrit, Eldad , Mevorach, Dror , Kleinstern, Geffen , Paltiel, Ora , Solomon, Abraham

Mayo Clinic

Journal of Immunology Research | January 21, 2019 | Volume: 2019 | Issue: No issue available | Pages: 1-9

10.1155/2019/9060842 | PMID 30805374 Get It

Objectives. To assess whether there are shared exposures associated with Sjogren’s syndrome (SS), dry eye syndrome (DES), and B-cell non-Hodgkin lymphoma (B-NHL), in order to determine whether they are etiologically related. Methods. In a clinic-based case-control study, 702 participants (91 SS, 120 DES, 211 (age and sex frequency-matched) controls, and 280 B-NHL cases) were recruited and interviewed regarding exposures, medical history, and family history. Results. Female predominance was noted in SS (ratio 9.2 : 1). Eye dryness was severest in SS compared to DES and controls (P<0.001). Compared to controls, alcohol consumption was inversely associated with NHL, DES, and SS (odds ratio OR=0.47, 95% confidence interval (CI): 0.31-0.71; OR=0.54, 95% CI: 0.33-0.88; and OR=0.26, 95% CI: 0.14-0.49, respectively), while a previous history of infection requiring hospitalization was positively associated with all three conditions: NHL (OR=1.92; 95% CI: 1.23-2.99), DES (OR=3.29; 95% CI: 1.97-5.47), and SS (OR=4.74; 95% CI: 2.66-8.44). NHL patients were more likely to report first-degree relatives with hematologic cancer, while having first-degree relatives with an autoimmune disease (AID) was associated with SS (OR=5.25; 95% CI: 2.59-10.63) and DES (OR=3.55; 95% CI: 1.83-6.91) compared to controls. Conclusions. Some exposures are associated with all three conditions (such as an inverse association with alcohol consumption and a positive association with serious past infection), while a family history of AID appears to be shared by DES and SS, but not NHL subjects. Shared risk factors for all three conditions indicate possible mutual etiological pathways.
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403
Stock, Wendy , Luger, Selina M. , Yin, Jun , Mullighan, Charles G. , Fulton, Noreen, Laumann, Kristina, Malnassy, Greg, Paietta, Elisabeth , Parker, Edy, Geyer, Susan, Mrózek, Krzysztof , Bloomfield, Clara D. , Sanford, Ben L. , Marcucci, Guido , Liedtke, Michaela , Claxton, David F. , Bogart, Jeffrey A. , Grecula, J.C., Appelbaum, Frederick R. , Litzow, Mark R. , Tallman, Martin S. , Stone, Richard M. , Mullighan, Charles G , Claxton, David F , Stock, Wendy , Advani, Anjali S. , Harvey, Richard C. , Willman, Cheryl L. , Foster, Matthew C , Erba, Harry Paul , Larson, Richard A.

Mayo Clinic

Blood | January 18, 2019 | Volume: 133 | Issue: 14 | Pages: 1548-1559

10.1182/blood-2018-10-881961 | PMID 30658992 Get It

Abstract Retrospective studies have suggested that older adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) have better survival rates when treated using a pediatric ALL regimen administered by pediatric treatment teams. To address the feasibility and efficacy of using a pediatric treatment regimen for AYA patients with newly diagnosed ALL administered by adult treatment teams, we performed a prospective study, CALGB 10403, with doses and schedule identical to those in the Children's Oncology Group study AALL0232. From 2007 to 2012, 318 patients were enrolled; 295 were eligible and evaluable for response. Median age was 24 years (range, 17-39 years). Use of the pediatric regimen was safe; overall treatment-related mortality was 3%, and there were only 2 postremission deaths. Median event-free survival (EFS) was 78.1 months (95% confidence interval [CI], 41.8 to not reached), more than double the historical control of 30 months (95% CI, 22-38 months); 3-year EFS was 59% (95% CI, 54%-65%). Median overall survival (OS) was not reached. Estimated 3-year OS was 73% (95% CI, 68%-78%). Pretreatment risk factors associated with worse treatment outcomes included obesity and presence of the Philadelphia-like gene expression signature. Use of a pediatric regimen for AYAs with ALL up to age 40 years was feasible and effective, resulting in improved survival rates compared with historical controls. CALGB 10403 can be considered a new treatment standard upon which to build for improving survival for AYAs with ALL. This trial was registered at www.clinicaltrials.gov as #NCT00558519.
Risk of Parkinson's disease dementia related to level I MDS PD‐MCI
Hoogland, Jeroen , Boel, Judith A., Bie, Rob M.A. de , Schmand, Ben , Geskus, Ronald B. , Dalrymple‐Alford, John C. , Adler, Charles H. , Junqué, Carme , Pedersen, Kenn Freddy , Mollenhauer, Brit , Goldman, Jennifer G. , Tröster, Alexander I. , Burn, David J. , Geurtsen, Gert J. , Disease”, on behalf of the MDS Study Group “Validation of Mild Cognitive Impairment in Parkinson, Adler, C H , Goldman, Jennifer G , Dalrymple-Alford, John C , de Bie, Rob M A , Geurtsen, Gert J , Junque, Carme , Marras, Connie , Weintraub, Daniel , Litvan, Irene , Disease”, on behalf of the MDS Study Group “Validation of Mild Cognitive Impairment in Parkinson

Mayo Clinic

Movement Disorders | January 17, 2019 | Volume: 34 | Issue: 3 | Pages: 430-435

10.1002/mds.27617 | PMID 30653248 Get It

AbstractBackgroundThe International Parkinson and Movement Disorders Society criteria for mild cognitive impairment in PD need validation. The objectives of this present study were to evaluate prognostic validity of level I (abbreviated) International Parkinson and Movement Disorders Society mild cognitive impairment in PD criteria for development of PD dementia and compared them with level II (comprehensive) criteria.MethodsWe analyzed data from 8 international studies (1045 patients) from our consortium that included baseline data on demographics, motor signs, depression, detailed neuropsychological testing, and longitudinal follow‐up for conversion to Parkinson's disease dementia. Survival analysis evaluated their contribution to the hazard of Parkinson's disease dementia.ResultsLevel I mild cognitive impairment in PD, increasing age, male sex, and severity of PD motor signs independently increased the hazard of Parkinson's disease dementia. Level I and level II mild cognitive impairment in PD classification had similar discriminative ability with respect to the time to Parkinson's disease dementia.ConclusionsLevel I mild cognitive impairment in PD classification independently contributes to the hazard of Parkinson's disease dementia. This finding supports the prognostic validity of the abbreviated mild cognitive impairment in PD criteria. © 2019 International Parkinson and Movement Disorder Society
Multiple myeloma and kidney transplantation: the beginning of a new era
bosch, Ines Van den, Sprangers, Ben , Gertz, Morie A.

Mayo Clinic

Clinical Kidney Journal | January 9, 2019 | Volume: 12 | Issue: 2 | Pages: 213-215

10.1093/ckj/sfz003 | PMID 30976398 Get It

Integrated Molecular Analysis of Undifferentiated Uterine Sarcomas Reveals Clinically Relevant Molecular Subtypes
Binzer-Panchal, Amrei , Hardell, Elin, Viklund, Björn, Ghaderi, Mehran , Bosse, Tjalling , Nucci, Marisa R. , Hollfelder, Nina , Corcoran, Pádraic, Gonzalez‐Molina, Jordi , Moyano‐Galceran, Lidia , Bell, Debra A., Schoolmeester, John K., Måsbäck, Anna , Kristensen, Gunnar B. , Davidson, Ben , Lehti, Kaisa , Carlson, Joseph W. , Hollfelder, Nina , Gonzalez-Molina, Jordi , Kristensen, Gunnar B , Lehti, Kaisa , Carlson, Joseph W , Lee, Cheng‐Han , Isaksson, Anders

Mayo Clinic

Clinical Cancer Research | January 7, 2019 | Volume: 25 | Issue: 7 | Pages: 2155-2165

10.1158/1078-0432.ccr-18-2792 | PMID 30617134 Get It

Abstract Purpose: Undifferentiated uterine sarcomas (UUS) are rare, extremely deadly, sarcomas with no effective treatment. The goal of this study was to identify novel intrinsic molecular UUS subtypes using integrated clinical, histopathologic, and molecular evaluation of a large, fully annotated, patient cohort. Experimental Design: Fifty cases of UUS with full clinicopathologic annotation were analyzed for gene expression (n = 50), copy-number variation (CNV, n = 40), cell morphometry (n = 39), and protein expression (n = 22). Gene ontology and network enrichment analysis were used to relate over- and underexpressed genes to pathways and further to clinicopathologic and phenotypic findings. Results: Gene expression identified four distinct groups of tumors, which varied in their clinicopathologic parameters. Gene ontology analysis revealed differential activation of pathways related to genital tract development, extracellular matrix (ECM), muscle function, and proliferation. A multivariable, adjusted Cox proportional hazard model demonstrated that RNA group, mitotic index, and hormone receptor expression influence patient overall survival (OS). CNV arrays revealed characteristic chromosomal changes for each group. Morphometry demonstrated that the ECM group, the most aggressive, exhibited a decreased cell density and increased nuclear area. A cell density cutoff of 4,300 tumor cells per mm2 could separate ECM tumors from the remaining cases with a sensitivity of 83% and a specificity of 94%. IHC staining of MMP-14, Collagens 1 and 6, and Fibronectin proteins revealed differential expression of these ECM-related proteins, identifying potential new biomarkers for this aggressive sarcoma subgroup. Conclusions: Molecular evaluation of UUS provides novel insights into the biology, prognosis, phenotype, and possible treatment of these tumors.
A phase II, multicenter, randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with carboplatin/paclitaxel as front-line therapy for optimally debulked primary ovarian cancer: The TRIO14 trial.
Konecny, Gottfried E. , Jänicke, F., Beckmann, Matthias W. , Feisel, Gabriele, Pölcher, Martin , Rody, Achim , Ray-Coquard, Isabelle Laure, Provencher, Diane , Ben‐Baruch, Noa, Cottu, Paul , Chen, Hsiao‐Wang, Dering, Judy, Jacod, Sylvie, Houé, Vincent, Slamon, Dennis J. , Haluska, Paul , Sehouli, Jalid , Roman, Lynda D. , Karlan, Beth Y. , Wang, Chen

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 5529-5529

10.1200/jco.2014.32.15_suppl.5529 Get It